ADC Therapeutics SA (ADCT) ニュース

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics to Present at November Investor Conferences PR Newswire LAUSANNE, Switzerland, Nov. 4, 2024...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Nov...

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 PR...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a...

ADC Therapeutics to Present at Upcoming Investor Conferences

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage...